Please assess the completion status of the following clinical trial:

Trial Title: Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography~* No signs or symptoms of congestive heart failure and who have not been hospitalized for heart failure~Exclusion criteria:~* Myocardial Infarction (MI) within 3 months of screening~* Unstable angina within 14 days of screening, or any evidence of myocardial ischemia~* Significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis~* Severe congenital heart diseases~* Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening~* Second or third degree heart block without a permanent cardiac pacemaker~* Stroke within 3 months of screening, or other evidence of significantly compromised central nervous system (CNS) perfusion~* Total bilirubin of \> 1.5 mg/dL or other liver enzymes \> 1.5 times the upper limit of normal (mg/dL = milligrams per deciliter)~* Serum creatinine of \> 3.0 mg/dL~* Serum sodium of \< 125 mEq/dL or \> 160 mEq/dL (milliequivalents per deciliter)~* Serum potassium of \< 3.5 mEq/dL or \> 5.0/dL~* Serum digoxin level of \> 2.0 ng/ml (nanograms per milliliter)~* Systolic pressure of \< 85 mm Hg (millimeters of mercury)~* Hemoglobin \< 10 gm/dl (grams per deciliter)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BNP (nesiritide) (Type: ACTIVE_COMPARATOR): BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)

Based on this trial design, predict the completion outcome and termination type (if applicable).